- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02522000
Functional Dyspepsia and Symptom Perception
Symptom Perception in Patients With Functional Dyspepsia: Involvement of the TRPV-1 Neuropeptide Pathway
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Annick Alleleyn, MD
- Phone Number: +31433884190
- Email: a.alleleyn@maastrichtuniversity.nl
Study Contact Backup
- Name: Fabiënne Smeets, MD
- Email: fabienne.smeets@maastrichtuniversity.nl
Study Locations
-
-
-
Maastricht, Netherlands, 6202 AZ
- Recruiting
- Maastricht University Medical Center (MUMC+)
-
Contact:
- Annick Alleleyn, MD
- Phone Number: +31433884190
- Email: a.alleleyn@maastrichtuniversity.nl
-
Contact:
- Fabiënne Smeets, MD
- Email: fabienne.smeets@maastrichtuniversity.nl
-
Principal Investigator:
- Jose Conchillo, MD PhD
-
Sittard-Geleen, Netherlands
- Not yet recruiting
- Zuyderland Medical Center
-
Contact:
- Annick Alleleyn, MD
- Phone Number: +31433884190
- Email: a.alleleyn@maastrichtuniversity.nl
-
Contact:
- Fabiënne Smeets, MD
- Email: fabienne.smeets@maastrichtuniversity.nl
-
Tilburg, Netherlands
- Not yet recruiting
- St. Elisabeth Medical Center
-
Contact:
- Annick Alleleyn, MD
- Phone Number: +31433884190
- Email: a.alleleyn@maastrichtuniversity.nl
-
Contact:
- Fabiënne Smeets, MD
- Email: fabienne.smeets@maastrichtuniversity.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Healthy volunteers
Inclusion criteria:
- No gastrointestinal symptoms or history of gastrointestinal disease meeting ROME III criteria for functional dyspepsia and Irritable Bowel Syndrome (IBS).
Exclusion criteria:
- Inability to stop the intake of nonsteroidal antiinflammatory drugs (NSAIDs) within 14 days prior to endoscopy and within two days prior to multi-sugar test.
- Inability to stop the intake of medication affecting gastrointestinal function (e.g. proton pump inhibitors, prokinetics, laxatives) within 5 days prior to endoscopy, multi-sugar test and combined meal- and gastric emptying test
- Current use of antidepressants
- Medical history of diabetes mellitus
- Medical history of coeliac disease
- Organic disease at upper gastrointestinal endoscopy (i.e. erosive esophagitis, Barrett's esophagus, benign esophageal stricture, Schatzki ring, esophageal carcinoma, esophageal candidiasis, gastric ulcer, gastric erosions, gastric cancer, duodenal erosions or duodenal ulcer)
- First-degree family members with diabetes mellitus type I, coeliac disease, Crohn's disease or ulcerative colitis
- Medical history of food allergy or anamnestic evidence of food allergy
- Presence of coagulation disorders or use of the following anticoagulants: coumarin derivates, new oral anticoagulants (NOACs: dabigatran, apixaban and rivaroxaban), and clopidogrel (Patients or healthy controls using calcium carbasalate (acetylsalicylic acid 100mg 1dd1) are eligible to participate in the study. Patients or healthy controls using higher doses of calcium carbasalate will be excluded from the study).
- Dieting
- Pregnancy or lactation
- Smoking
- Excessive alcohol use (>20 alcoholic consumptions/week) and inability to avoid use of alcohol in the 2 days prior to endoscopy and multi-sugar test
Functional dyspepsia patients
Inclusion criteria:
- Patients referred for upper gastrointestinal endoscopy by either general practitioners or physicians from the gastroenterology outpatient clinic and meeting ROME III criteria for functional dyspepsia.
Exclusion criteria:
- Inability to stop the intake of nonsteroidal antiinflammatory drugs (NSAIDs) within 14 days prior to endoscopy and within two days prior to multi-sugar test.
- Inability to stop the intake of medication affecting gastrointestinal function (e.g. proton pump inhibitors, prokinetics, laxatives) within 5 days prior to endoscopy, multi-sugar test and combined meal- and gastric emptying test
- Current use of antidepressants
- Medical history of diabetes mellitus
- Medical history of coeliac disease
- Organic disease at upper gastrointestinal endoscopy (i.e. erosive esophagitis, Barrett's esophagus, benign esophageal stricture, Schatzki ring, esophageal carcinoma, esophageal candidiasis, gastric ulcer, gastric erosions, gastric cancer, duodenal erosions or duodenal ulcer)
- First-degree family members with diabetes mellitus type I, coeliac disease, Crohn's disease or ulcerative colitis
- Medical history of food allergy or anamnestic evidence of food allergy
- Presence of coagulation disorders or use of the following anticoagulants: coumarin derivates, new oral anticoagulants (NOACs: dabigatran, apixaban and rivaroxaban), and clopidogrel (Patients or healthy controls using calcium carbasalate (acetylsalicylic acid 100mg 1dd1) are eligible to participate in the study. Patients or healthy controls using higher doses of calcium carbasalate will be excluded from the study).
- Dieting
- Pregnancy or lactation
- Smoking
- Excessive alcohol use (>20 alcoholic consumptions/week) and inability to avoid use of alcohol in the 2 days prior to endoscopy and multi-sugar test
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Healthy controls
|
Patients with functional dyspepsia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TRPV-1 neuropeptide pathway (TRPV-1 and mucosal neuropeptides)
Time Frame: Test day 1: mucosal biopsies are taken during upper gastrointestinal endoscopy
|
The primary outcome measure is the TRPV-1 neuropeptide pathway which includes both TRPV-1 and mucosal neuropeptide concentrations (e.g.
substance P, somatostatin), assessed with real time polymerase chain reaction (PCR) and radioimmunoassay respectively.
|
Test day 1: mucosal biopsies are taken during upper gastrointestinal endoscopy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom scores for psychopathology
Time Frame: 14-day period between testday 1 and testday 2
|
The Patient Health Questionnaire 9 (PHQ-9) and GAD-7 questionnaires will be used for the assessment of depressive and anxiety disorders respectively. During 7 consecutive days a digital device will be carried out for assessment of symptoms several times a day (experience sampling method/ESM). |
14-day period between testday 1 and testday 2
|
Symptom scores for dyspepsia
Time Frame: 14-day period between testday 1 and testday 2
|
Dyspeptic symptoms will be measured with two questionnaires to acquire more detailed information about complaints in patients with functional dyspepsia. The dyspepsia symptom questionnaire and the symptom checklist of the Nepean Dyspepsia Index will be used to grade the presence and intensity of dyspeptic symptoms. In addition, participants will report dyspeptic symptoms during 14 consecutive days in an end-of-day diary. During 7 consecutive days a digital device will be carried out for assessment of symptoms several times a day (experience sampling method/ESM). |
14-day period between testday 1 and testday 2
|
Symptom scores for quality of life
Time Frame: This questionnaire is fulfilled once, in the 14-day period between testday 1 and testday 2
|
Quality of life will be assessed with the Health Survey 26 (SF-36) questionnaire.
|
This questionnaire is fulfilled once, in the 14-day period between testday 1 and testday 2
|
Postprandial symptoms after ingestion of a standardized meal
Time Frame: Testday 2: Postprandial symptoms are scored using a Likert scale at 15-minute intervals for a period of 240 minutes postprandial.
|
Testday 2: Postprandial symptoms are scored using a Likert scale at 15-minute intervals for a period of 240 minutes postprandial.
|
|
In vivo gastroduodenal and small intestinal permeability
Time Frame: Day before testday 2
|
Gastroduodenal en small intestinal permeability will be assessed with a multisugar test.
|
Day before testday 2
|
Transcription of genes encoding for proteins involved in mucosal barrier function and symptom perception
Time Frame: Testday 1: gastric and duodenal biopsies are taken during upper gastrointestinal endoscopy.
|
Testday 1: gastric and duodenal biopsies are taken during upper gastrointestinal endoscopy.
|
|
Serotonin metabolism in mucosal tissue
Time Frame: Testday 1: gastric and duodenal biopsies are taken during upper gastrointestinal endoscopy
|
Testday 1: gastric and duodenal biopsies are taken during upper gastrointestinal endoscopy
|
|
Serotonin metabolism in plasm
Time Frame: Testday 2: blood samples for serotonin analyses are taken preprandial and every 30 minutes after intake of a standardized meal during 240 minutes postprandial.
|
Testday 2: blood samples for serotonin analyses are taken preprandial and every 30 minutes after intake of a standardized meal during 240 minutes postprandial.
|
|
Gastric emptying for solids using the 13C-sodium octanoate stable isotope breath test
Time Frame: Testday 2: Repeated measure: breath samples for analysis of gastric emptying are taken preprandial and every 15 minutes after intake of a standardized meal during 240 minutes postprandial.
|
Testday 2: Repeated measure: breath samples for analysis of gastric emptying are taken preprandial and every 15 minutes after intake of a standardized meal during 240 minutes postprandial.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jose Conchillo, MD, PhD, Maastricht University Medical Center, Maastricht, The Netherlands
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- METC142070
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspepsia
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
-
Dong-A ST Co., Ltd.Not yet recruitingFunctional DyspepsiaKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Zeria PharmaceuticalRecruitingFunctional DyspepsiaJapan
-
Hong Kong Baptist UniversityXiyuan Hospital of China Academy of Chinese Medical SciencesRecruitingFunctional DyspepsiaHong Kong
-
Seoul National University HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Wonju Severance Christian HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedFunctional DyspepsiaKorea, Republic of